Clinical Trials

27 enrolled

NSCLC

NCT07472478 2026-03-16

GIVEN

32 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

596 enrolled

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT05378334 2026-03-10

Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients

82 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06385262 2026-03-06

TOP 2301: Neoadjuvant Chemo for NSCLC

Phase 2 Suspended

126 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07452003 2026-03-05

An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC

Carcinoma, Non-Small-Cell Lung

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

47 enrolled

Phase 3 Active not recruiting

Small Cell Lung Carcinoma

NCT03774732 2026-02-25

NIRVANA-LUNG

327 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04798664 2026-02-25

Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening

Phase NA Completed

3,228 enrolled 41 charts

Lung Neoplasms, Tobacco Use Disorder, Smoking Cessation

NCT07425795 2026-02-23

Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer

36 enrolled

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT07408635 2026-02-13

IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

43 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT07398937 2026-02-10

ECTOP-1036

116 enrolled

Lung Neoplasms

NCT04297605 2026-02-09

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Phase 1 Recruiting

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06610734 2026-02-09

SKY

202 enrolled

Small Cell Lung Cancer Extensive Stage

NCT05488626 2026-02-05

ARTIA-Lung

Phase NA Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT07358676 2026-01-22

A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

25 enrolled

Small Cell Lung Carcinoma

NCT04151940 2026-01-14

PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer

80 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07330596 2026-01-09

QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC

96 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06899126 2026-01-08

DESTINY-Lung06

Phase 3 Recruiting

686 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06877299 2026-01-02

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02153229 2025-12-26

MPM-PDT

52 enrolled

Other solid neoplasmThoracic

Epitheliod Malignant Pleural Mesothelioma

NCT07293247 2025-12-22

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

164 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07171606 2025-12-18

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

240 enrolled

First-line Advanced NSCLC Patients

NCT06102057 2025-12-17

PACCELIO

110 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07274384 2025-12-10

HYPERBOLIC

74 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT07271602 2025-12-09

A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.

104 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05440916 2025-12-02

PRIMM

Phase 2 Completed

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07258147 2025-12-02

Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

Lung Neoplasms

NCT07247227 2025-11-25

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

150 enrolled

NSCLC

NCT06652048 2025-11-21

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06228326 2025-10-24

KYANITE-1

Phase 1/2 Recruiting

250 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05468489 2025-10-21

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

200 enrolled

Extensive Stage Small Cell Lung Cancer

NCT05775796 2025-10-01

Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)

Phase 2 Completed

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07190027 2025-09-24

Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial

246 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06840782 2025-09-15

OliGRAIL

Phase 3 Recruiting

124 enrolled

Phase 2/3 Active not recruiting

Oligometastatic Non-small Cell Lung Cancer (NSCLC)

NCT07145333 2025-09-08

Drug-SNP

600 enrolled

SCLC

NCT06784791 2025-08-29

NEOpredict-EGF

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07139041 2025-08-24

Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC

69 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07135882 2025-08-22

PRIME-Lung

420 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07134413 2025-08-21

QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC

77 enrolled